Condition

mCRPC

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 20 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials20
Recruiting8
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

20 shown
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerNCT07751133 · 2026-08-28
RECRUITING
A Study in Patients With Metastatic Castration-Resistant Prostate CancerNCT07719361 · 2026-07-01
RECRUITING
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate CancerNCT07581184 · 2026-06-17
RECRUITING
A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate CancerNCT07853209 · 2026-01-26
RECRUITING
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)NCT07103018 · 2025-11-21
RECRUITING
The Radium-select StudyNCT06659926 · 2025-02-24
RECRUITING
A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate CancerNCT07096128 · 2024-08-20
RECRUITING
Anti-tumour Activity of (177Lu) rhPSMA-10.1 InjectionNCT05413850 · 2022-07-20
RECRUITING
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult ParticipantsNCT07850921 · 2027-06-28
NOT_YET_RECRUITING
Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT07389187 · 2026-02-01
NOT_YET_RECRUITING
Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)NCT07104643 · 2025-08-01
NOT_YET_RECRUITING
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate CancerNCT06866548 · 2025-03-10
ACTIVE_NOT_RECRUITING
Study of INKmune in Patients With mCRPC (CaRe Prostate)NCT06056791 · 2023-11-30
COMPLETED
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate CancerNCT05340374 · 2022-07-14
ACTIVE_NOT_RECRUITING
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard TherapyNCT05547061 · 2021-04-12
ACTIVE_NOT_RECRUITING
Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry StudyNCT06830408 · 2020-07-06
COMPLETED
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 ProtocolNCT04145375 · 2019-11-12
ENROLLING_BY_INVITATION
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCNCT03395197 · 2017-12-18
ACTIVE_NOT_RECRUITING
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsNCT02266745 · 2014-07-01
UNKNOWN
Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)NCT01818986 · 2013-07-10
COMPLETED

Common interventions

Trial status mix

RECRUITING8
ACTIVE_NOT_RECRUITING4
COMPLETED3
NOT_YET_RECRUITING3
ENROLLING_BY_INVITATION1
UNKNOWN1

Phase mix

PHASE111
PHASE29
PHASE33
EARLY_PHASE12
NA1
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.